The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025

LONDON, Dec. 13, 2018 /PRNewswire/ -- Anticoagulants Market by Drug Class (NOACs, Heparin & LMWH, Vitamin K Antagonist, and Others), Route of Administration (Oral Anticoagulant and Injectable Anticoagulant), and Application (Atrial Fibrillation & Heart Attack, Stroke, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Others) - Global Opportunity Analysis and Industry Forecast, 2018-2025

Download the full report: https://www.reportbuyer.com/product/5563986

The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025. Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood and prolong the clotting time. The market has different types of anticoagulant drugs, and each drug works by inhibiting various pathways of blood coagulation. These drugs are majorly used for high risk of blood clots, such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others.

The global anticoagulants market is expected to grow at a significant rate during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disease across the world, growing adoption of novel oral anticoagulants (NOACs), and growing awareness of NOACs in developing regions. Furthermore, increasing obese and geriatric population and growing demand of novel therapeutics are anticipated to further influence the market growth during the forecast period. On the other side, higher price of NOACs and lack of antidots for NOACs impede the market growth.

The global anticoagulants market is segmented based on drug class, route of administration, application, and region. On the basis of drug class, the anticoagulants market is classified as NOACs, heparin & LMWH, vitamin K antagonist, and others. As per the route of administration, the market is segmented as oral anticoagulant and injectable anticoagulant. Application market-wise, it is classified as atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others.

According to region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By drug class
NOACs
Eliquis
Bevyxxa
Xarelto
Savaysa & lixiana
Pradaxa
Heparin & LMWH
Vitamin K antagonist
Others

By route of administration
Oral anticoagulant
Injectable anticoagulant

By application
Atrial fibrillation & heart attack
Stroke
Deep vein thrombosis (DVT)
Pulmonary embolism (PE)
Others

By region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
Aspen Holdings
Bayer AG
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
GlaxoSmithKline plc.
Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Pfizer, Inc.
Portola Pharmaceuticals, Inc.
Sanofi S.A.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request).
Armetheon, Inc.
Astrazeneca
Celgene Corporation

Download the full report: https://www.reportbuyer.com/product/5563986

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer